OMNIAB, INC. Payments to Acquire Debt Securities, Available-for-sale
OMNIAB, INC. (OABI) reported Payments to Acquire Debt Securities, Available-for-sale of $33.01 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-06
- OMNIAB, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $23.61M, a 183.25% increase year-over-year.
- OMNIAB, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $9.40M, a 8.40% decline year-over-year.
- OMNIAB, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $8.28M, a 43.36% decline year-over-year.
- OMNIAB, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $19.98M, a 122.43% increase year-over-year.
- OMNIAB, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $46.86M, a 16.31% increase from fiscal 2024.
- OMNIAB, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $40.29M, a 64.23% decline from fiscal 2023.
- OMNIAB, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $112.62M, a 105.60% increase from fiscal 2022.
- OMNIAB, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $54.77M.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $23.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $33.01M 10-Q · filed 2026-08-06 | $41.29M derived: sum of 3 quarters · filed 2026-08-06 | $61.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $9.40M 10-Q · filed 2026-05-07 | $17.68M derived: sum of 2 quarters · filed 2026-05-07 | $37.66M derived: sum of 3 quarters · filed 2026-05-07 | $46.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $8.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $28.26M derived: sum of 2 quarters · filed 2026-03-04 | $36.60M derived: sum of 3 quarters · filed 2026-08-06 | $46.86M 10-K · filed 2026-03-04 |
| 2025-09-30 | $19.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $28.32M derived: sum of 2 quarters · filed 2026-08-06 | $38.58M 10-Q · filed 2025-11-04 | $53.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $8.34M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $18.59M 10-Q · filed 2026-08-06 | $33.21M derived: sum of 3 quarters · filed 2026-08-06 | $42.20M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $10.26M 10-Q · filed 2026-05-07 | $24.88M derived: sum of 2 quarters · filed 2026-05-07 | $33.86M derived: sum of 3 quarters · filed 2026-05-07 | $45.13M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $14.62M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $23.60M derived: sum of 2 quarters · filed 2026-03-04 | $34.87M derived: sum of 3 quarters · filed 2026-03-04 | $40.29M 10-K · filed 2026-03-04 |
| 2024-09-30 | $8.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $20.25M derived: sum of 2 quarters · filed 2025-11-04 | $25.67M 10-Q · filed 2025-11-04 | $51.40M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $11.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $16.68M 10-Q · filed 2025-08-06 | $42.42M derived: sum of 3 quarters · filed 2025-08-06 | $73.11M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $5.42M 10-Q · filed 2025-05-08 | $31.15M derived: sum of 2 quarters · filed 2025-05-08 | $61.84M derived: sum of 3 quarters · filed 2025-05-08 | $78.97M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $25.73M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $56.42M derived: sum of 2 quarters · filed 2025-03-18 | $73.55M derived: sum of 3 quarters · filed 2025-03-18 | $112.62M 10-K · filed 2025-03-18 |
| 2023-09-30 | $30.69M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $47.82M derived: sum of 2 quarters · filed 2024-11-12 | $86.89M 10-Q · filed 2024-11-12 | $141.66M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $17.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $56.20M 10-Q · filed 2024-08-08 | $110.97M derived: sum of 3 quarters · filed 2024-08-08 | $110.97M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $39.06M 10-Q · filed 2024-05-09 | $93.84M derived: sum of 2 quarters · filed 2024-05-09 | $93.84M derived: sum of 3 quarters · filed 2024-05-09 | $93.84M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $54.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $54.77M derived: sum of 2 quarters · filed 2024-03-25 | $54.77M derived: sum of 3 quarters · filed 2024-03-25 | $54.77M 10-K · filed 2024-03-25 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 derived: sum of 2 quarters · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| OneMedNet Corp (ONMD) | $0.042B | ||
| iSpecimen Inc. (ISPC) | United States | $0.003B | |
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |